Ferrous sulphate dose for anemia
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that ferrous sulphate is effective for treating anemia in various populations, including infants, children, pregnant women, and heart failure patients, with considerations for dosage and potential side effects.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta19 papers analyzed
Optimal Ferrous Sulfate Dose for Anemia Treatment
Introduction to Ferrous Sulfate for Anemia
Ferrous sulfate is a commonly prescribed oral iron supplement used to treat iron deficiency anemia (IDA). It is favored due to its effectiveness in increasing hemoglobin and ferritin levels. This article synthesizes research findings on the optimal dosing of ferrous sulfate for treating anemia in various populations.
Standard Dosing Regimens
Daily vs. Twice Daily Dosing in Pregnant Women
Research comparing once daily (65 mg elemental iron) and twice daily (130 mg elemental iron) dosing of ferrous sulfate in pregnant women found that both regimens were effective in preventing anemia. However, the twice daily regimen resulted in significantly higher hemoglobin levels but also more side effects, suggesting that a once daily dose may be preferable for better compliance and fewer side effects.
Single vs. Multiple Daily Doses in Infants
A study on infants aged 6-24 months compared the efficacy of single daily doses (40 mg elemental iron) versus three-times-daily doses of ferrous sulfate drops. The results showed similar rates of successful anemia treatment and minimal side effects in both groups, indicating that a single daily dose could improve adherence without compromising efficacy.
Comparative Efficacy in Special Populations
Cancer Patients with Mild IDA
In cancer patients with mild non-chemotherapy-induced IDA, a study compared the efficacy of ferrous bisglycinate chelate and ferrous sulfate. Patients receiving 105 mg of ferrous sulfate daily for 60 days showed significant improvements in hemoglobin and ferritin levels, similar to those receiving ferrous bisglycinate chelate, but with a higher incidence of gastrointestinal side effects.
Heart Failure Patients
For heart failure patients with IDA, a study demonstrated that 200 mg of ferrous sulfate taken three times daily significantly improved functional capacity over 12 weeks compared to a placebo. This suggests that higher doses may be necessary in populations with concurrent chronic conditions to achieve functional improvements.
Alternative Iron Supplementation Methods
Intravenous Iron vs. Oral Ferrous Sulfate in Pregnancy
A study comparing intravenous (IV) iron preparations to daily oral ferrous sulfate (325 mg) in pregnant women found that IV iron (ferric carboxymaltose and iron polymaltose) resulted in significantly higher increases in hemoglobin and ferritin levels at four weeks. However, compliance with oral iron was lower, indicating that while oral ferrous sulfate is effective, IV iron may be more suitable for rapid repletion of iron stores.
Microencapsulated Iron Sprinkles
An innovative approach using microencapsulated ferrous fumarate plus ascorbic acid in powder form (sprinkles) was compared to ferrous sulfate drops in infants. Both methods were equally effective in treating anemia, but the ease of use of sprinkles may improve adherence, making it a viable alternative to traditional drops.
Conclusion
Ferrous sulfate remains a cornerstone in the treatment of iron deficiency anemia across various populations. Daily dosing regimens, particularly a single daily dose, are generally effective and may improve adherence due to fewer side effects. In special populations, such as pregnant women and heart failure patients, higher doses or alternative methods like IV iron may be necessary for optimal outcomes. Further research and individualized treatment plans are essential to maximize the benefits of iron supplementation while minimizing adverse effects.
Sources and full results
Most relevant research papers on this topic
